Johnson & Johnson Innovative Medicine

At Johnson & Johnson Innovative Medicine, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Johnson & Johnson Innovative Medicine

November 24, 2022

Data science in early drug discovery – getting it right from the start

The application of data science in the early stages of drug development is not new – progress in algorithms and computing power has been ongoing for years. We have reached the point where we have to reflect on the road travelled and look forward to upcoming opportunities and challenges. To further pave the way and reach the top in health data science, stakeholders will have to find each other and work together. Once everyone is on board, data science knows no bounds!

December 6, 2021

Unlocking doors: Key considerations for start-ups during Discovery and Development

for Johnson & Johnson Innovative Medicine

Mark Hicken is Vice President of Strategy for Europe, Middle East and Africa (EMEA) at the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). With more than 20 years of experience in the company, Mark leads a cross-functional team that drives Janssen’s continued growth across the region, in close collaboration with the local operating companies. On the 28th of October, Mark presented a talk during an online event hosted by Johnson & Johnson Innovation – JLABS (JLABS) ‘Start at the End: Thinking Commercial during Discovery and Development’ (recording available here). Following the webinar, Mark shared some additional insights and advice with us.

September 30, 2020

Get to know Lewis Cantley: winner of the 2020 Dr. Paul Janssen Award

Every year, the Dr. Paul Janssen Award for Biomedical Research is granted to a scientist who embodies the eponymous man’s dedication to his patients and unfailing curiosity and passion for scientific progress. The 2020 winner of this prestigious award is Dr. Lewis Cantley, who discovered the family of PI3K enzymes, thereby increasing our understanding of a wide range of diseases including cancer and diabetes. Nearly 30 years on from this seminal discovery, Dr. Cantley’s research has resulted in more precise cancer therapies that have saved patient lives, making him a true champion of science.

August 21, 2020

Lewis Cantley awarded Dr. Paul Janssen Award for Biomedical Research 2020

for Johnson & Johnson Innovative Medicine

Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of Science® Initiative - Lewis Cantley, Ph.D. Named 2020 Award Winner for the Discovery of PI3K Enzyme and its Role in Wide Range of Diseases from Diabetes to Cancer

March 24, 2020

Janssen Pharmaceutica and Filliers Distillery make disinfectant hand gel

for Johnson & Johnson Innovative Medicine

Pharmaceutical company Janssen Pharmaceutica and gin distillery Filliers Distillery are making disinfectant hand gel from Sunday. They will distribute it among the Belgian hospitals.

August 27, 2019

Meet the men who unraveled the mystery of protein folding

for Johnson & Johnson Innovative Medicine

December 14, 2018

A microbiome solution for type 1 diabetes?

for Johnson & Johnson Innovative Medicine

November 28, 2018

A Personal Translation of Microbiome Futures

for Johnson & Johnson Innovative Medicine

October 16, 2018

Lessons in Herding Cats: Business Development for Life Sciences Companies

for Johnson & Johnson Innovative Medicine

September 18, 2018

Saving lives through fundamental research: James Allison wins Dr. Paul Janssen Award 2018

for Johnson & Johnson Innovative Medicine

August 28, 2018

Janssen to team up with UGent and UZ Gent in industry-academia collaboration

for Johnson & Johnson Innovative Medicine

Janssen Pharmaceutica have signed a renewal of the innovation charter with Ghent University (UGent) and Ghent University Hospital (UZ Gent). The move is part of an initiative to share more knowledge and expertise between industry and academia, stimulating scientific progress and reaching patients faster than ever before.